MarginsXMarginsX
Home › Markets › Health Care › ORMP

Oramed Pharmaceuticals Inc. (ORMP)

ORMP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.90
+5.12% on the day
Market cap
$169.6M
Micro cap
Revenue · 2025
$2.0M
Prior year not contiguous
Net income · 2025
$64.0M
3202.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/0001213900-26-034835-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerORMP on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIsrael
IPO yearNot reported by the screener
SEC CIK0001176309
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$2.0M
Net income$64.0M
Operating income-$15.1M
Net margin3202.5%
Operating margin-754.4%
Revenue growthNo prior-year revenue to compare
Cash$45.9M
Total assets$230.9M
P/E (computed)2.6×
P/S (computed)84.8×

Warning signs

Cash runway
110.1 months
$28.9M cash at September 30, 2026
Share count, 1 year
+9.3%
2025-11-12 to 2026-11-11 · +7.8% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
-$942K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$28.9M cash; operating cash flow -$789K a quarter.Report 2026-09-30
Shares outstanding43,485,942 (2026-11-11); 39,802,455 a year earlier; 40,338,979 three years earlier.Cover page 2026-11-11
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKesselman & Kesselman C.P.A.s, Tel-Aviv, IsraelPCAOB Form AP 2026-04-12
Late filings, 12 months1 NT noticeNT 10-Q 2026-05-15
Insider trades, 12 monthsBought $0, sold $942K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-09-30
Not filed$18.4M$426K$28.9MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2026-06-30
Not filed$78.2M-$200K$15.2MNo debt tagsNeeds four quarters10-Q 2026-08-10
Q2 2026
2026-03-31
Not filed$38.3M-$2.9M$13.2MNo debt tagsNeeds four quarters10-Q 2026-05-19
Q1 2026
2025-12-31
$0$10.0M-$466K$45.9M$652K$2.0M10-K 2026-03-26
Q1 2026
2025-09-30
$0$48.4M-$1.6M$52.2M$1KNeeds four quarters10-Q 2026-11-12
Q3 2025
2025-06-30
$0$13.3M-$3.5M$15.8M$34KNeeds four quarters10-Q 2026-08-10
Q2 2025
2025-03-31
$2.0M-$7.6M-$3.5M$74.5M$36KNeeds four quarters10-Q 2026-05-19
Q1 2025
2024-12-31
Not filed-$10.2M-$1.9M$54.4M$329KNeeds four quarters10-K 2026-03-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS SUPPLEMENT
424B52024-03-18
Latest annual report
ANNUAL REPORT
10-K2026-03-26
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-12
Latest current report
CURRENT REPORT
8-K2026-09-17
Latest proxy
DEFINITIVE ADDITIONAL MATERIALS
DEFA14A2026-08-03

Source: SEC EDGAR submissions feed, 951 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.9%
1 month-11.0%
3 months-15.3%
Year to date+30.2%
1 year+54.6%
From 52-week high-30.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ANTXAN2 Therapeutics Inc.$4.47-1.76%$169.6M
PYXSPyxis Oncology Inc.$1.41-10.76%$168.6M
PRQRProQR Therapeutics N.V.$1.18-16.31%$166.5M
ELDNEledon Pharmaceuticals Inc.$1.97-6.86%$166.4M
IFRXInflaRx N.V.$1.18+0.85%$173.9M
KRROKorro Bio Inc.$12.71-6.61%$174.5M
WHWKWhitehawk Therapeutics Inc.$3.01-1.63%$177.6M
SLGLSol-Gel Technologies Ltd.$54.96-0.29%$179.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier